Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,371
  • Shares Outstanding, K 13,797
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,200 K
  • EBIT $ -30 M
  • EBITDA $ -30 M
  • 60-Month Beta 1.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.88

Options Overview Details

View History
  • Implied Volatility 141.06% ( -19.94%)
  • Historical Volatility 73.50%
  • IV Percentile 23%
  • IV Rank 23.18%
  • IV High 472.50% on 12/13/23
  • IV Low 41.03% on 09/27/24
  • Put/Call Vol Ratio 0.27
  • Today's Volume 761
  • Volume Avg (30-Day) 633
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 17,158
  • Open Int (30-Day) 17,322

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.38
  • Number of Estimates 1
  • High Estimate -0.38
  • Low Estimate -0.38
  • Prior Year -1.09
  • Growth Rate Est. (year over year) +65.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.68 +2.10%
on 11/15/24
10.54 -35.29%
on 10/28/24
-2.39 (-25.95%)
since 10/18/24
3-Month
6.68 +2.10%
on 11/15/24
10.54 -35.29%
on 10/28/24
-1.71 (-20.05%)
since 08/16/24
52-Week
4.53 +50.55%
on 07/02/24
22.49 -69.68%
on 12/27/23
+0.75 (+12.36%)
since 11/17/23

Most Recent Stories

More News
Annovis Bio (NYSE: ANVS) Concludes Q3 with Milestones, FDA-Cleared Phase 3 Program for Alzheimer’s

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 6.82 (-0.29%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...

ANVS : 6.82 (-0.29%)
LLY : 727.20 (-2.55%)
INMB : 4.87 (-1.72%)
XBI : 91.96 (+0.14%)
BIIB : 157.94 (-1.28%)
SAVA : 27.95 (+3.86%)
Annovis Bio (NYSE: ANVS) CEO to Showcase Buntanetap’s Dual Benefits at NIA Workshop

Annovis Bio (NYSE: ANVS) announced that its President and CEO, Dr. Maria Maccecchini, will speak at the National Institute on Aging’s (NIA) workshop, “Dementia with Lewy Bodies: Filling the Gaps in...

ANVS : 6.82 (-0.29%)
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

ANVS : 6.82 (-0.29%)
Annovis Bio (NYSE: ANVS) Advances Alzheimer’s Phase 3 Trials with Strong FDA Support, Financial Backing

Annovis Bio (NYSE: ANVS) provided a third-quarter update, announcing significant progress in developing its lead drug candidate, buntanetap, for Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 6.82 (-0.29%)
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update

ANVS : 6.82 (-0.29%)
Annovis Bio (NYSE: ANVS) Strengthens Clinical Research Team with Appointment of Senior Clinical Scientist

Annovis Bio (NYSE: ANVS) has appointed Dr. Matthew Peterson as Senior Clinical Scientist, bolstering the team as it approaches pivotal Phase 3 trials for its neurodegenerative disease therapies, including...

ANVS : 6.82 (-0.29%)
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

ANVS : 6.82 (-0.29%)
Annovis Bio (NYSE: ANVS) Highlights Buntanetap Results at 17th Clinical Trials on Alzheimer’s Disease Conference

Annovis (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”),...

ANVS : 6.82 (-0.29%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Small biotech firms like Cassava Sciences, INmune Bio, and Annovis Bio are developing innovative Alzheimer’s treatments, disrupting big pharma’s dominance in the $13.7B market. For those targeting...

ANVS : 6.82 (-0.29%)
LLY : 727.20 (-2.55%)
INMB : 4.87 (-1.72%)
XBI : 91.96 (+0.14%)
BIIB : 157.94 (-1.28%)
SAVA : 27.95 (+3.86%)

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 7.22
2nd Resistance Point 7.09
1st Resistance Point 6.96
Last Price 6.82
1st Support Level 6.70
2nd Support Level 6.57
3rd Support Level 6.44

See More

52-Week High 22.49
Fibonacci 61.8% 15.63
Fibonacci 50% 13.51
Fibonacci 38.2% 11.39
Last Price 6.82
52-Week Low 4.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar